These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. [Fatal interstitial lung disease associated with erlotinib use]. Eshuis M; Ahsmann EJ; van Egmond NH Ned Tijdschr Geneeskd; 2013; 157(7):A5519. PubMed ID: 23406641 [TBL] [Abstract][Full Text] [Related]
27. The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. Grossi F; Rijavec E; Dal Bello MG; Defferrari C; Brianti A; Barletta G; Genova C; Murolo C; Cosso M; Fontanini G; Boldrini L; Truini M; Pronzato P Cancer Chemother Pharmacol; 2012 Jun; 69(6):1407-12. PubMed ID: 22349923 [TBL] [Abstract][Full Text] [Related]
28. Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer. Timmers L; Boons CC; Moes-Ten Hove J; Smit EF; van de Ven PM; Aerts JG; Swart EL; Boven E; Hugtenburg JG J Cancer Res Clin Oncol; 2015 Aug; 141(8):1481-91. PubMed ID: 25743274 [TBL] [Abstract][Full Text] [Related]
29. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA; J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829 [TBL] [Abstract][Full Text] [Related]
30. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer. Zhou S; Ren S; Yan L; Zhang L; Tang L; Zhang J; Zhou C Respirology; 2009 Jul; 14(5):709-15. PubMed ID: 19659649 [TBL] [Abstract][Full Text] [Related]
31. [Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib]. Böker B; Lüders H; Grohé C Pneumologie; 2012 Feb; 66(2):89-95. PubMed ID: 22337328 [TBL] [Abstract][Full Text] [Related]
33. The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients. Wojas-Krawczyk K; Krawczyk P; Mlak R; Kucharczyk T; Kowalski DM; Krzakowski M; Milanowski J Respiration; 2011; 82(4):341-50. PubMed ID: 21242665 [TBL] [Abstract][Full Text] [Related]
34. Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer. Juhász E; Kim JH; Klingelschmitt G; Walzer S Eur J Cancer; 2013 Apr; 49(6):1205-15. PubMed ID: 23477998 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer. Merimsky O; Cheng CK; Au JS; von Pawel J; Reck M Oncol Rep; 2012 Aug; 28(2):721-7. PubMed ID: 22614912 [TBL] [Abstract][Full Text] [Related]
36. Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer. Becker A; van Wijk A; Smit EF; Postmus PE J Thorac Oncol; 2010 Sep; 5(9):1477-80. PubMed ID: 20736807 [TBL] [Abstract][Full Text] [Related]
37. EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival. Faehling M; Eckert R; Kamp T; Kuom S; Griese U; Sträter J; Ott G; Spengler W Lung Cancer; 2013 Jun; 80(3):306-12. PubMed ID: 23489557 [TBL] [Abstract][Full Text] [Related]
39. Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient. Tsubata Y; Hamada A; Sutani A; Isobe T J Cancer Res Ther; 2012; 8(1):154-6. PubMed ID: 22531540 [TBL] [Abstract][Full Text] [Related]
40. Erlotinib-associated alopecia in a lung cancer patient. Costa DB; Kobayashi S; Schumer ST J Thorac Oncol; 2007 Dec; 2(12):1136-8. PubMed ID: 18090591 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]